Chimerix, Inc. has extended its contract with the Biomedical Advanced Research and Development Authority (BARDA) for the continued development of CMX001 as a potential countermeasure against smallpox. The extension provides $5 million in funding for the next 12 months for Chimerix to conduct animal studies necessary for an approval of CMX001 for treatment of smallpox infection under the FDA Animal Efficacy Rule.   CMX001 is being developed as a treatment or preventive therapeutic for multiple vi...